Cladribine: not just another purine analogue? - PubMed (original) (raw)

Review

Cladribine: not just another purine analogue?

Stephen Spurgeon et al. Expert Opin Investig Drugs. 2009 Aug.

Abstract

Cladribine was synthesized as a purine analogue drug that inhibited adenosine deaminase. It received FDA approval in the 1980s for treatment of hairy cell leukemia. Given its toxicity towards lymphocytes and its corresponding immunosuppressive effects, it has been studied and found efficacious in a variety of hematologic malignancies and autoimmune conditions, most recently multiple sclerosis. This review highlights pharmacological, toxicological and clinical data for the use of cladribine. It also discusses existing and new mechanisms that may contribute to its unique clinical activity. Emerging data show that in addition to its known purine nucleoside analogue activity, cladribine possesses epigenetic properties, inhibiting S-adenosylhomocysteine hydrolase and DNA methylation. This may contribute to its efficacy and highlights the importance of studying combination therapy with other epigenetic or targeted agents. Clinical trials are underway in a variety of malignant and nonmalignant conditions.

PubMed Disclaimer

Similar articles

• [Cladribine].
  Ogura M. Ogura M. Gan To Kagaku Ryoho. 2003 Feb;30(2):309-17. Gan To Kagaku Ryoho. 2003. PMID: 12610885 Review. Japanese.
• Cladribine. Ortho Biotech Inc.
  Tortorella C, Rovaris M, Filippi M. Tortorella C, et al. Curr Opin Investig Drugs. 2001 Dec;2(12):1751-6. Curr Opin Investig Drugs. 2001. PMID: 11892941 Review.
• Cladribine: from the bench to the bedside--focus on hairy cell leukemia.
  Greyz N, Saven A. Greyz N, et al. Expert Rev Anticancer Ther. 2004 Oct;4(5):745-57. doi: 10.1586/14737140.4.5.745. Expert Rev Anticancer Ther. 2004. PMID: 15485311 Review.
• 2-Chloro-2'-deoxyadenosine (2CdA) biochemical aspects of antileukemic efficacy.
  Fabianowska-Majewska K, Wyczechowska D. Fabianowska-Majewska K, et al. Acta Pol Pharm. 1996 Jul-Aug;53(4):231-9. Acta Pol Pharm. 1996. PMID: 9415193 Review.
• Cladribine for multiple sclerosis: review and current status.
  Sipe JC. Sipe JC. Expert Rev Neurother. 2005 Nov;5(6):721-7. doi: 10.1586/14737175.5.6.721. Expert Rev Neurother. 2005. PMID: 16274330 Review.

Cited by

• Decitabine as epigenetic priming with CLAG induce improved outcome of relapsed or refractory acute myeloid leukemia in children.
  Zhang N, Li H, Wang D, Wang Z, Zhu JS, Chen K, Jiang H, Shao JB, Cai C. Zhang N, et al. Clin Epigenetics. 2024 May 9;16(1):63. doi: 10.1186/s13148-024-01677-z. Clin Epigenetics. 2024. PMID: 38725010 Free PMC article.
• Retrospective Evaluation of Hairy Cell Leukemia Patients: Analysis of a Long-Term Single Center Data.
  Biglari M, Kamranzadeh Foumani H, Bagherian M, Chahardouli B, Ghavamzadeh A. Biglari M, et al. Int J Hematol Oncol Stem Cell Res. 2022 Oct 1;16(4):209-216. doi: 10.18502/ijhoscr.v16i4.10878. Int J Hematol Oncol Stem Cell Res. 2022. PMID: 36883111 Free PMC article.
• Magnetic Multi-Enzymatic System for Cladribine Manufacturing.
  Cruz G, Saiz LP, Bilal M, Eltoukhy L, Loderer C, Fernández-Lucas J. Cruz G, et al. Int J Mol Sci. 2022 Nov 7;23(21):13634. doi: 10.3390/ijms232113634. Int J Mol Sci. 2022. PMID: 36362425 Free PMC article.
• Combined epigenetic and immunotherapy for blastic and classical mantle cell lymphoma.
  LeBlanc FR, Hasanali ZS, Stuart A, Shimko S, Sharma K, Leshchenko VV, Parekh S, Fu H, Zhang Y, Martin MM, Kester M, Fox T, Liao J, Loughran TP, Evans J, Pu JJ, Spurgeon SE, Aladjem MI, Epner EM. LeBlanc FR, et al. Oncotarget. 2022 Aug 16;13:986-1002. doi: 10.18632/oncotarget.28258. eCollection 2022. Oncotarget. 2022. PMID: 36093297 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Taylor & Francis

• Other Literature Sources

  • The Lens - Patent Citations

• Research Materials

  • NCI CPTC Antibody Characterization Program